These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36806485)

  • 1. Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review.
    Das A; Sil A; Khan IA; Bandyopadhyay D
    Clin Exp Dermatol; 2023 Jun; 48(6):599-608. PubMed ID: 36806485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Molica M; Alimena G
    Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
    Li J; Wang M; Zhang B; Wu X; Lin TL; Liu XF; Zhou Y; Zhang XH; Xu H; Shen LJ; Zou J; Lu P; Zhang D; Gu WJ; Zhang MX; Pan J; Cao H;
    World J Gastroenterol; 2018 Dec; 24(46):5189-5202. PubMed ID: 30581268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine side effects of broad-acting kinase inhibitors.
    Lodish MB; Stratakis CA
    Endocr Relat Cancer; 2010 Sep; 17(3):R233-44. PubMed ID: 20603395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice.
    Yan M; Li W; Li WB; Huang Q; Li J; Cai HL; Gong H; Zhang BK; Wang YK
    Drug Metab Rev; 2023; 55(1-2):94-106. PubMed ID: 36453523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
    Hartmann JT; Haap M; Kopp HG; Lipp HP
    Curr Drug Metab; 2009 Jun; 10(5):470-81. PubMed ID: 19689244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.
    de Lavallade H; Khoder A; Hart M; Sarvaria A; Sekine T; Alsuliman A; Mielke S; Bazeos A; Stringaris K; Ali S; Milojkovic D; Foroni L; Chaidos A; Cooper N; Gabriel I; Apperley J; Belsey S; Flanagan RJ; Goldman J; Shpall EJ; Kelleher P; Marin D; Rezvani K
    Blood; 2013 Jul; 122(2):227-38. PubMed ID: 23719297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of target small molecule tyrosine kinase inhibitors that need monitoring and clinical application of protocol for early detection of cancer therapeutics-related cardiac dysfunction using signal detection: An investigation of real world data.
    Mizuno T; Sakai T; Tanabe K; Kozaki K; Umemura T; Higashikawa M; Kimura T; Yamada T; Goto N; Ohtsu F
    J Oncol Pharm Pract; 2021 Jun; 27(4):804-814. PubMed ID: 32539664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.
    Shah DR; Shah RR; Morganroth J
    Drug Saf; 2013 Jun; 36(6):413-26. PubMed ID: 23620170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surufatinib in neuroendocrine tumours.
    Das M
    Lancet Oncol; 2019 Apr; 20(4):e196. PubMed ID: 30880071
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology.
    Shah RR; Shah DR
    Drug Saf; 2019 Feb; 42(2):181-198. PubMed ID: 30649743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
    Aghel N; Delgado DH; Lipton JH
    Leukemia; 2018 Oct; 32(10):2095-2104. PubMed ID: 30201984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.
    Amitay-Laish I; Stemmer SM; Lacouture ME
    Dermatol Ther; 2011; 24(4):386-95. PubMed ID: 21910796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Translated article] The needs and medication experience of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A systematic review.
    Cachafeiro Pin AI; Villaverde Piñeiro L; Martín Clavo S; Silva Castro MM
    Farm Hosp; 2023; 47(2):T85-T92. PubMed ID: 36870818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials.
    Liu JW; Chen C; Loh EW; Chu CC; Wang MY; Ouyang HJ; Chang YT; Zhuang WZ; Chou CW; Huang DJ; Lee CH; Yen Y; Tam KW
    Curr Med Res Opin; 2018 May; 34(5):795-803. PubMed ID: 28812918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
    Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K
    Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.
    Sodergren SC; White A; Efficace F; Sprangers M; Fitzsimmons D; Bottomley A; Johnson CD
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):35-46. PubMed ID: 24495942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.